{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:13:50Z","timestamp":1793150030754,"version":"4.5.0"},"reference-count":186,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T00:00:00Z","timestamp":1481155200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["105402\/Z\/14\/Z"],"award-info":[{"award-number":["105402\/Z\/14\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Microbiology"],"published-print":{"date-parts":[[2017,9,3]]},"DOI":"10.1080\/1040841x.2016.1242868","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T23:55:19Z","timestamp":1481241319000},"page":"521-545","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":51,"title":["Iminosugars: Promising therapeutics for influenza infection"],"prefix":"10.1080","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-6419","authenticated-orcid":false,"given":"Beatrice Ellen","family":"Tyrrell","sequence":"first","affiliation":[{"name":",","place":["United Kingdom of Great Britain and Northern Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Cameron","family":"Sayce","sequence":"additional","affiliation":[{"name":",","place":["United Kingdom of Great Britain and Northern Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly Lyn","family":"Warfield","sequence":"additional","affiliation":[{"name":"Antiviral Research and Development, Emergent BioSolutions Inc, Gaithersburg, MD, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4383-4641","authenticated-orcid":false,"given":"Joanna Louise","family":"Miller","sequence":"additional","affiliation":[{"name":",","place":["United Kingdom of Great Britain and Northern Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1969-4949","authenticated-orcid":false,"given":"Nicole","family":"Zitzmann","sequence":"additional","affiliation":[{"name":",","place":["United Kingdom of Great Britain and Northern Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,12,8]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010372"},{"key":"#cr-split#-e_1_3_3_3_1.1","unstructured":"Alios Biopharma Inc. [Internet] A study of AL-794 to evaluate the safety tolerability and pharmacokinetics of single and multiple doses and the antiviral activity of multiple doses in an influenza challenge study. 2015 [updated 2016 Jan 20"},{"key":"#cr-split#-e_1_3_3_3_1.2","unstructured":"cited 2016 Jul 8]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02588521."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070748"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002745.pub4"},{"key":"e_1_3_3_6_1","unstructured":"Amarillo Biosciences Inc. [Internet] Interferon alpha lozenges plus oseltamivir for influenza treatment. 2010 [updated 2013 Aug 19; last accessed 25 Jul 2015]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01146535."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(99)00384-6"},{"key":"e_1_3_3_8_1","unstructured":"Ansun Biopharma Inc. [Internet] Phase 2B study on safety and therapeutic efficacy of DAS181 in adult subjects with naturally acquired influenza. 2012 [updated 2013 Jul 11; last accessed 5 Jun 2015]. Available from: https:\/\/clinicaltrials.gov\/show\/NCT01740063."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470517437.ch2"},{"key":"e_1_3_3_10_1","unstructured":"Autoimmune Technologies LLC. [Internet] FF-3 the first cell-entry-inhibiting influenza drug. [date unknown; last accessed 29 Apr 2016]. Available from: http:\/\/www.autoimmune.com\/FF-3.html."},{"key":"e_1_3_3_11_1","doi-asserted-by":"crossref","unstructured":"Autoimmune Technologies LLC. [Internet] Safety and protective efficacy of FF-3\u2009dry powder in healthy subjects infected with influenza challenge strain. 2015 [updated 2016 Jun 21; last accessed 8 Jul 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02423577.","DOI":"10.1016\/j.fopow.2015.12.012"},{"key":"e_1_3_3_12_1","first-page":"23","article-title":"[Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial]","volume":"57","author":"Aver'ianov A","year":"2012","unstructured":"Aver'ianov A, Babkin A, Bart B, et\u00a0al. (2012). [Ergoferon and oseltamivir in treatment of influenza: results of multicentre randomized comparative clinical trial]. [abstract] Antibiot Khimioter. 57:23\u201330. Russian.","journal-title":"Antibiot Khimioter"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm0002679"},{"key":"e_1_3_3_14_1","first-page":"35","article-title":"Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity","volume":"40","author":"Baum LG","year":"1990","unstructured":"Baum LG, Paulson JC. (1990). Sialyloligosaccharides of the respiratory epithelium in the selection of human influenza virus receptor specificity. Acta Histochem 40:35\u20138.","journal-title":"Acta Histochem"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(91)90003-T"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12094"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2014.11.006"},{"key":"e_1_3_3_18_1","unstructured":"Beth Israel Deaconess Medical Center. [Internet] Statin therapy in acute influenza. 2013 [updated 2016 Jan 18; last accessed 29 Apr 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02056340."},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.7665.1"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.04.006"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0598-610"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.6.2235"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1989.tb14792.x"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(84)90103-X"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.039"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05223.x"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0854.2000.010702.x"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/5.2.249"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1984.tb01845.x"},{"key":"e_1_3_3_30_1","unstructured":"Centers for Disease Control and Prevention. [Internet] Influenza type A viruses and subtypes. 2013 [last accessed 5 Jan 2015]. Available from: http:\/\/www.cdc.gov\/flu\/avianflu\/influenza-a-virus-subtypes.htm."},{"key":"e_1_3_3_31_1","unstructured":"Centers for Disease Control and Prevention. [Internet] What you should know for the 2014-2015 influenza season. 2015 [last accessed 23 Apr 2015]. Available from: http:\/\/www.cdc.gov\/flu\/about\/season\/flu-season-2014-2015.htm."},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.06.011"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.08.003"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.03.023"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.81503-0"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049224"},{"key":"e_1_3_3_37_1","unstructured":"Chinese University of Hong Kong. [Internet] Anti-inflammatory effects of macrolide treatment in influenza lower respiratory tract infections. 2013 [updated 2016 Jul 25; last accessed 1 Sep 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01779570."},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm5007275"},{"key":"e_1_3_3_39_1","unstructured":"Consortium for Functional Genomics. [Internet] Symbol and text nomenclature for representation of glycan structure. 2012 [last accessed 26 Apr 2015]. Available from: http:\/\/www.functionalglycomics.org\/static\/consortium\/Nomenclature.shtml."},{"key":"e_1_3_3_40_1","first-page":"373","article-title":"Ilotycin (erythromycin) in the treatment of A prime influenza","volume":"54","author":"Cronk GA","year":"1954","unstructured":"Cronk GA, Naumann DE. (1954). Ilotycin (erythromycin) in the treatment of A prime influenza. N Y State J Med 54:373\u20135.","journal-title":"N Y State J Med"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2009.12.014"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(02)00821-3"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01309294"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.144.3620.862"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70821-7"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.19.8987-8998.2001"},{"key":"e_1_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.7.5.582"},{"key":"e_1_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd708"},{"key":"e_1_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)68070-1"},{"key":"e_1_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(84)90232-7"},{"key":"e_1_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)90761-1"},{"key":"e_1_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)55439-9"},{"key":"e_1_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.08.038"},{"key":"e_1_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.11.6.946"},{"key":"e_1_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/10.1.77"},{"key":"e_1_3_3_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.69.9.5791-5797.1995"},{"key":"e_1_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.10.7153-7160.1996"},{"key":"e_1_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.09.015"},{"key":"e_1_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.977-981.2002"},{"key":"e_1_3_3_60_1","first-page":"40","article-title":"New chemopreparation arbidol: its prophylactic effectiveness during influenza epidemics","volume":"70","author":"Gagarinova VM","year":"1993","unstructured":"Gagarinova VM, Ignatyeva GS, Sinitskaya LV, et\u00a0al. (1993). New chemopreparation arbidol: its prophylactic effectiveness during influenza epidemics. [abstract] Zhurnal Mikrobiologii Epidemiologii I Immunobiologii 70:40\u20133 (Russian).","journal-title":"Zhurnal Mikrobiologii Epidemiologii I Immunobiologii"},{"key":"e_1_3_3_61_1","doi-asserted-by":"crossref","first-page":"7136","DOI":"10.1128\/jvi.66.12.7136-7145.1992","article-title":"Glycosylation requirements for intracellular transport and function of the hemagglutinin of influenza virus","volume":"66","author":"Gallagher PJ","year":"1992","unstructured":"Gallagher PJ, Henneberry JM, Sambrook JF, Gething MJ. (1992). Glycosylation requirements for intracellular transport and function of the hemagglutinin of influenza virus. J Virol 66:7136\u201345.","journal-title":"J Virol"},{"key":"e_1_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1998.9224"},{"key":"e_1_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1999.9732"},{"key":"e_1_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R110.129809"},{"key":"e_1_3_3_65_1","unstructured":"Genentech Inc. [Internet] A study of MHAA4549A in combination with oseltamivir versus oseltamivir in patients with severe influenza A infection. 2014 [updated 2016 Jul 1; last accessed 8 Jul 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02293863."},{"key":"e_1_3_3_66_1","unstructured":"GlaxoSmithKline. [Internet] Safety tolerability and clinical effect of danirixin in adults with influenza. 2015 [updated 2016 Jun 27; last accessed 8 Jul 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02469298."},{"key":"e_1_3_3_67_1","article-title":"Statins block influenza infection by down-regulating Rho\/rho kinase pathway","volume":"116","author":"Haidari M","year":"2007","unstructured":"Haidari M, Ali M, Casscells SW, Madjid M. (2007). Statins block influenza infection by down-regulating Rho\/rho kinase pathway. Circulation 116:Abstract 147.","journal-title":"Circulation"},{"key":"e_1_3_3_68_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.3.913"},{"key":"e_1_3_3_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90395-X"},{"key":"e_1_3_3_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1996.tb00659.x"},{"key":"e_1_3_3_71_1","doi-asserted-by":"publisher","DOI":"10.1101\/SQB.1995.060.01.045"},{"key":"e_1_3_3_72_1","unstructured":"Hospices Civils de Lyon. [Internet] Confirmation of the antiviral effects of midodrine identified with a gene expression signature-based screening of inluenza A virus infected cells (FLUMED). 2012 [updated 2015 Jan 7; last accessed 29 Jul 2015]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01546506."},{"key":"e_1_3_3_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)81283-E"},{"key":"e_1_3_3_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12171"},{"key":"e_1_3_3_75_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2907"},{"key":"e_1_3_3_76_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.108.6.2117"},{"key":"e_1_3_3_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku349"},{"key":"e_1_3_3_78_1","unstructured":"Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited. [Internet] Banlangen granules anti-seasonal influenza study (BLG). 2012 [updated 2016 Mar 2; last accessed 29 Jul 2015]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02232945."},{"key":"e_1_3_3_79_1","doi-asserted-by":"crossref","first-page":"7436","DOI":"10.1128\/jvi.67.12.7436-7443.1993","article-title":"The hemagglutinins of duck and human H1 influenza viruses differ in sequence conservation and in glycosylation","volume":"67","author":"Inkster MD","year":"1993","unstructured":"Inkster MD, Hinshaw VS, Schulze IT. (1993). The hemagglutinins of duck and human H1 influenza viruses differ in sequence conservation and in glycosylation. J Virol 67:7436\u201343.","journal-title":"J Virol"},{"key":"e_1_3_3_80_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.9.7367-7373.1998"},{"key":"e_1_3_3_81_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013169"},{"key":"e_1_3_3_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.073"},{"key":"e_1_3_3_83_1","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S36601"},{"key":"e_1_3_3_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/8.7.725"},{"key":"e_1_3_3_85_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3290511"},{"key":"e_1_3_3_86_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3230415"},{"key":"e_1_3_3_87_1","doi-asserted-by":"crossref","first-page":"17278","DOI":"10.1016\/S0021-9258(19)77832-6","article-title":"Selective inhibition of glycoprotein-processing enzymes. Differential inhibition of glucosidases I and II in cell culture","volume":"263","author":"Kaushal GP","year":"1988","unstructured":"Kaushal GP, Pan YT, Tropea JE, et\u00a0al. (1988). Selective inhibition of glycoprotein-processing enzymes. Differential inhibition of glucosidases I and II in cell culture. J Biol Chem 263:17278\u201383.","journal-title":"J Biol Chem"},{"key":"e_1_3_3_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-621-0_1"},{"key":"e_1_3_3_89_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.122.6.1253"},{"key":"e_1_3_3_90_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja963036t"},{"key":"e_1_3_3_91_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.54.070185.003215"},{"key":"e_1_3_3_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.07.025"},{"key":"e_1_3_3_93_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-328"},{"key":"e_1_3_3_94_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.67.11.6667-6673.1993"},{"key":"e_1_3_3_95_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00607-16"},{"key":"e_1_3_3_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70730-3"},{"key":"e_1_3_3_97_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-8-200610170-00139"},{"key":"e_1_3_3_98_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1470-1479.2006"},{"key":"e_1_3_3_99_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.3.1987"},{"key":"e_1_3_3_100_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024207931650"},{"key":"e_1_3_3_101_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.18.8502-8512.2000"},{"key":"e_1_3_3_102_1","unstructured":"MedImmune LLC. [Internet] A phase 1b\/2a to evaluate the safety of MEDI8852 in adults with uncomplicated influenza (MEDI8852). 2015 [updated 2016 Mar 8; last accessed 8 Jul 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02603952."},{"key":"e_1_3_3_103_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/872370"},{"key":"e_1_3_3_104_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20031824"},{"key":"e_1_3_3_105_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20031822"},{"key":"e_1_3_3_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(20)71210-X"},{"key":"e_1_3_3_107_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/649570"},{"key":"e_1_3_3_108_1","doi-asserted-by":"publisher","DOI":"10.1038\/47062"},{"key":"e_1_3_3_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)38272-9"},{"key":"e_1_3_3_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2013.06.004"},{"key":"e_1_3_3_111_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.11.117"},{"key":"e_1_3_3_112_1","unstructured":"[NIAID] National Institute of Allergy and Infectious Diseases. [Internet] Safety and efficacy of investigational anti-influenza immune plasma in treating influenza (IRC002). 2010 [updated 2016 Aug 12; last accessed 15 Aug 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01052480."},{"key":"e_1_3_3_113_1","unstructured":"[NIAID] National Institute of Allergy and Infectious Diseases. [Internet] Testing the AVI-7100 flu drug in healthy volunteers. 2012 [updated 2016 July 6; last accessed 8 Jul 2016]. Available from: https:\/\/clinicaltrials.gov\/show\/NCT01747148."},{"key":"e_1_3_3_114_1","unstructured":"[NIAID] National Institute of Allergy and Infectious Diseases. [Internet] Evaluating the safety and efficacy of anti-influenza intravenous hyperimmune immunoglobulin (IVIG) in adults hospitalized with influenza. 2014 [updated 2016 Jan 13; last accessed 7 Jul 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02287467."},{"key":"e_1_3_3_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.04.012"},{"key":"e_1_3_3_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)81795-1"},{"key":"e_1_3_3_117_1","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.46.1883"},{"key":"e_1_3_3_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(91)90588-3"},{"key":"e_1_3_3_119_1","doi-asserted-by":"publisher","DOI":"10.1002\/9780470517437.ch9"},{"key":"e_1_3_3_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/0003-9861(85)90771-4"},{"key":"e_1_3_3_121_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00285a038"},{"key":"e_1_3_3_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.01.004"},{"key":"e_1_3_3_123_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00028-15"},{"key":"e_1_3_3_124_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32830efd96"},{"key":"e_1_3_3_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu539"},{"key":"e_1_3_3_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(89)90249-3"},{"key":"e_1_3_3_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(83)90150-2"},{"key":"e_1_3_3_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(83)90133-2"},{"key":"e_1_3_3_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.07.014"},{"key":"e_1_3_3_130_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.029470"},{"key":"e_1_3_3_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(90)90186-U"},{"key":"e_1_3_3_132_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.59.923"},{"key":"e_1_3_3_133_1","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.62.575"},{"key":"e_1_3_3_134_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.1.324"},{"key":"e_1_3_3_135_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00155a013"},{"key":"e_1_3_3_136_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004524"},{"key":"e_1_3_3_137_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2010.04.003"},{"key":"e_1_3_3_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)38590-3"},{"key":"e_1_3_3_139_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.118.2.227"},{"key":"e_1_3_3_140_1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1128\/jvi.4.1.58-66.1969","article-title":"Functional significance of sialidase during influenza virus multiplication: an electron microscope study","volume":"4","author":"Seto JT","year":"1969","unstructured":"Seto JT, Chang FS. (1969). Functional significance of sialidase during influenza virus multiplication: an electron microscope study. J Virol 4:58\u201366.","journal-title":"J Virol"},{"key":"e_1_3_3_141_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.81.6.1779"},{"key":"e_1_3_3_142_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.69.1.531"},{"key":"e_1_3_3_143_1","doi-asserted-by":"publisher","DOI":"10.1177\/095632020601700403"},{"key":"e_1_3_3_144_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/141.5.548"},{"key":"e_1_3_3_145_1","first-page":"683","article-title":"The results of controlled observations on the prophylaxis of influenza with interferon","volume":"41","author":"Solov\u2019ev VD.","year":"1969","unstructured":"Solov\u2019ev VD. (1969). The results of controlled observations on the prophylaxis of influenza with interferon. Bull World Health Organ 41:683\u20138.","journal-title":"Bull World Health Organ"},{"key":"e_1_3_3_146_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121662"},{"key":"e_1_3_3_147_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.21401"},{"key":"e_1_3_3_148_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/10.7.649"},{"key":"e_1_3_3_149_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022844"},{"key":"e_1_3_3_150_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004851"},{"key":"e_1_3_3_151_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/4.2.141"},{"key":"e_1_3_3_152_1","doi-asserted-by":"publisher","DOI":"10.3390\/v6031294"},{"key":"e_1_3_3_153_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1502374112"},{"key":"e_1_3_3_154_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-83-5-1137"},{"key":"e_1_3_3_155_1","unstructured":"Tyms AS. Virogen Ltd. (2003). Use of certain castanospermine esters in the treatment of influenza virus infections. African Intellectual Property Organization African Regional Intellectual Property Organization Eurasian Patent Organization European Patent Office United States Patent Office. Patent WO2003006017."},{"key":"e_1_3_3_156_1","unstructured":"Unither Virology. [Internet] Study to determine the safety tolerability and pharmacokinetics of UV-4B solution administered orally in healthy subjects. 2014 [updated 2016 Jan 28; last accessed 6 Jul 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02061358."},{"key":"e_1_3_3_157_1","unstructured":"University of Hong Kong. [Internet] Treatment of severe influenza A infection. 2014 [updated 2015 Nov 30; last accessed 8 Jul 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02108366."},{"key":"e_1_3_3_158_1","first-page":"23","article-title":"Ergoferon and improvement of etiopathogenetic therapy of influenza and acute respiratore viral infection in adults","volume":"56","author":"Verevshchikov VK","year":"2011","unstructured":"Verevshchikov VK, Borzunov VM, Shemiakina EK. (2011). Ergoferon and improvement of etiopathogenetic therapy of influenza and acute respiratore viral infection in adults. [abstract] Antibiot Khimioter 56:23\u20136 (Russian).","journal-title":"Antibiot Khimioter"},{"key":"e_1_3_3_159_1","doi-asserted-by":"publisher","DOI":"10.1038\/286771a0"},{"key":"e_1_3_3_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2007.03.003"},{"key":"e_1_3_3_161_1","unstructured":"Visterra Inc. [Internet] Influenza challenge study of VIS410 in healthy volunteers. 2015 [updated 2016 Apr 4; last accessed 8 Jul 2016]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02468115."},{"key":"e_1_3_3_162_1","doi-asserted-by":"publisher","DOI":"10.1038\/363418a0"},{"key":"e_1_3_3_163_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.352"},{"key":"e_1_3_3_164_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M806897200"},{"key":"e_1_3_3_165_1","doi-asserted-by":"publisher","DOI":"10.3390\/v8030071"},{"key":"e_1_3_3_166_1","doi-asserted-by":"publisher","DOI":"10.3390\/v7052404"},{"key":"e_1_3_3_167_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.03.001"},{"key":"e_1_3_3_168_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.56.070187.002053"},{"key":"e_1_3_3_169_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196909112811102"},{"key":"e_1_3_3_170_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161209787846775"},{"key":"e_1_3_3_171_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.11.2574"},{"key":"e_1_3_3_172_1","unstructured":"[WHO] World Health Organisation. (1980). A revision of the system of nomenclature for influenza viruses: a WHO Memorandum. Bull W H O. 58:585-591."},{"key":"e_1_3_3_173_1","unstructured":"[WHO] World Health Organisation. [Internet] Influenza (Seasonal) Fact sheet Number 211. 2014 [last accessed 4 Jan 2015]. Available from: http:\/\/www.who.int\/mediacentre\/factsheets\/fs211\/en\/."},{"key":"e_1_3_3_174_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.8.3596-3604.2002"},{"key":"e_1_3_3_175_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.12.139"},{"key":"e_1_3_3_176_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00333-08"},{"key":"e_1_3_3_177_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/7.2.297"},{"key":"e_1_3_3_178_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2015.09.008"},{"key":"e_1_3_3_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2013.04.009"},{"key":"e_1_3_3_180_1","doi-asserted-by":"publisher","DOI":"10.4149\/av_2013_01_85"},{"key":"e_1_3_3_181_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.8.10.1943"},{"key":"e_1_3_3_182_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2014.12.006"},{"key":"e_1_3_3_183_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711942105"},{"key":"e_1_3_3_184_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc070359"},{"key":"e_1_3_3_185_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.21.11878"},{"key":"e_1_3_3_186_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.117.3.551"}],"container-title":["Critical Reviews in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1040841X.2016.1242868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1040841X.2016.1242868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:01:37Z","timestamp":1770915697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1040841X.2016.1242868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,8]]},"references-count":186,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9,3]]}},"alternative-id":["10.1080\/1040841X.2016.1242868"],"URL":"https:\/\/doi.org\/10.1080\/1040841x.2016.1242868","relation":{},"ISSN":["1040-841X","1549-7828"],"issn-type":[{"value":"1040-841X","type":"print"},{"value":"1549-7828","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imby20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imby20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-05-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-09-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}